Findings

What do systematic reviews say?

28 questions · 28 findings · 4 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 7 · 25%GRADE not reported 3 · 10.7%Very low 4 · 14.3%Low 10 · 35.7%Moderate 4 · 14.3%High 0 · 0%

Oral tetracycline vs topical clindamycin

Participant global assessment VAS Visual analogue scale (VAS) (0 to 100 mm) · participants with hidradenitis suppurativa

1 finding from 1 review

Interventions for hidradenitis suppurativa 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 34 participants
Low

Oral tetracycline vs topical clindamycin

Pain VAS VAS (0 to 100 mm) · participants with hidradenitis suppurativa

1 finding from 1 review

Interventions for hidradenitis suppurativa 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 34 participants
Low

Oral tetracycline vs topical clindamycin

Nodules score Nodule count · participants with hidradenitis suppurativa

1 finding from 1 review

Interventions for hidradenitis suppurativa 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 34 participants
Low

Oral tetracycline vs topical clindamycin

Abscesses score Abscess count · participants with hidradenitis suppurativa

1 finding from 1 review

Interventions for hidradenitis suppurativa 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 34 participants
Low

Oral tetracycline vs topical clindamycin

Physician global assessment VAS VAS (0 to 100 mm) · participants with hidradenitis suppurativa

1 finding from 1 review

Interventions for hidradenitis suppurativa 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 34 participants
Low

Macrolide+tetracycline vs macrolides

Quality of life, measured by CRQ (dyspnoea, fatigue, emotional function, and mastery subscales) · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 187 participants
Very low

Macrolide+tetracycline vs macrolides

All‐cause serious adverse events 60 weeks (end of study) · patients with chronic obstructive pulmonary disease

It is very uncertain whether macrolide+tetracycline changes all‐cause serious adverse events 60 weeks (end of study) compared with macrolide (very low certainty).

1 finding from 1 review

Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes only
OR 1 [0.52, 1.93]
1 study · 198 participants
Very low

Macrolide+tetracycline vs macrolides

Change in baseline trough FEV1 · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 182 participants
Very low

Macrolide+tetracycline vs macrolides

All‐cause mortality 60 weeks (end of study) · patients with chronic obstructive pulmonary disease

It is very uncertain whether macrolide+tetracycline changes all‐cause mortality 60 weeks (end of study) compared with macrolide (very low certainty).

1 finding from 1 review

Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes only
OR 1.63 [0.38, 7.02]
1 study · 198 participants
Very low

Macrolide+tetracycline vs macrolides

Number of people experiencing one or more exacerbations, Drug resistance/microbial sensitivity (as reported by trialists), including emergence of atypical bacteria, Number of participants colonised with Pseudomonas aeruginosa · patients with chronic obstructive pulmonary disease

The review found no eligible studies for this question.

1 finding from 1 review

Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Macrolides vs tetracycline

Exacerbations (number of people experiencing ≥ 1 exacerbations) · patients with chronic obstructive pulmonary disease

Macrolide showed no clear difference in number of participants experiencing one or more exacerbations… compared with tetracycline (low certainty).

1 finding from 1 review

Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes only
OR 0.44 [0.14, 1.38]
1 study · 50 participants
Low

Quinolone vs tetracycline

Exacerbations (number of people experiencing ≥ 1 exacerbations) · patients with chronic obstructive pulmonary disease

Quinolone showed no clear difference in number of participants experiencing one or more exacerbations… compared with tetracycline (low certainty).

1 finding from 1 review

Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes only
OR 0.44 [0.14, 1.38]
1 study · 50 participants
Low

Oral azithromycin vs topical tetracycline

Active trachoma · people (any age) with active trachoma

1 finding from 1 review

Antibiotics for trachoma 2019 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 6002 participants
Low

Oral azithromycin vs topical tetracycline

Ocular chlamydia trachomatis infection · people (any age) with active trachoma

1 finding from 1 review

Antibiotics for trachoma 2019 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 5773 participants
Low

Oral azithromycin vs topical tetracycline

Antibiotic resistance · people (any age) with active trachoma

The review found no eligible studies for this question.

1 finding from 1 review

Antibiotics for trachoma 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oral azithromycin vs topical tetracycline

Adverse effects · people (any age) with active trachoma

1 finding from 1 review

Antibiotics for trachoma 2019 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 6002 participants
GRADE not reported

Topical metronidazole vs oral (oxy)tetracycline

HRQOL ‐ not measured · Participants with rosacea

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for rosacea 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Topical metronidazole vs oral (oxy)tetracycline

Participant‐assessed improvement in rosacea severity · Participants with rosacea

1 finding from 1 review

Interventions for rosacea 2015 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 182 participants
Moderate

Topical metronidazole vs oral (oxy)tetracycline

Proportion of participants with adverse event · Participants with rosacea

1 finding from 1 review

Interventions for rosacea 2015 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 258 participants
Moderate

Topical metronidazole vs oral (oxy)tetracycline

Physician‐assessed improvement in rosacea severity · Participants with rosacea

1 finding from 1 review

Interventions for rosacea 2015 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 81 participants
Moderate